Cutaneous castleman's disease responds to anti interleukin-6 treatment.
Castleman's disease is uncommon, and cutaneous involvement is even rarer. We report a 42-year-old Asian woman with the multicentric plasma cell variant of Castleman's disease limited to her skin. The literature suggests that Castleman's disease is driven by interleukin-6 (IL-6). Based on these data, we hypothesized that suppression of IL-6 would have a salutary effect. Therefore, our patient was treated with CNTO328, a chimeric murine anti-human IL-6 antibody. She has shown a remarkable, ongoing response to this treatment, with almost complete clearing of her skin lesions after six doses.
Ahmed
Bilal
B
Phase I Program, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Box 422, Houston, TX 77030, USA. rkurzroc@mdanderson.org
Tschen
Jaime A
JA
Cohen
Philip R
PR
Zaki
Mohamed H
MH
Rady
Peter L
PL
Tyring
Stephen K
SK
Corringham
Robert E
RE
Kurzrock
Razelle
R
D000328:Adult; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use*; D005871:Castleman Disease / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D005260:Female; D006801:Humans; D015850:Interleukin-6 / Q000737:chemistry / Q000276:immunology* / Q000627:therapeutic use; D010950:Plasma Cells / Q000187:drug effects* / Q000276:immunology / Q000473:pathology; D011379:Prognosis; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology
D000911:Antibodies, Monoclonal; D015850:Interleukin-6